The developing of technology for diagnostics of genetic variants, that determine the sensitivity to warfarin, using the single nucleotide primer extension method
Abstract
Warfarin is prescribed to a lot of patients with different pathologies, however there are individual differences of required dosage up to twenty times. Overdosage can cause health complications like different localized bleeding, up to if threatening condition. There are genetics factors, that influences on warfarin metabolism in the human body. The point of this research is the development of set of oligonucleotide and genotyping of genetic polymorphism, that influence on warfarin effect. The developed multiplex panel (мультиплексная панель) includes six polymorphic variants in biotransformation genes, and their combination determine correct warfarin dose: CYP2C9 (rs1799853, rs1057910), VKORC1 (rs9923231, rs8050894), CYP4F2 (rs2108622) and GGCX (rs11676382).Genetic replacement types and DNA characteristics in SNP region were analysed to develop the sample set. The multiplexing opportunity was checked according to the results of the reaction with Primer Focus Kit. Multiplex genotyping of DNA control samples with known genotypes was performed. Genotypes wich were identified using SNaPshot, corresponds to those, indentified using standard method. In summary, sample panel for multiplex genotyping of six SNP was developed and verified, SNP are connected with individual warfarin sensibility. Using these results in clinical practice can increase efficiency of anticoagulant therapy and decrease side effects frequency.
About the Authors
N. P. Babushkina
Research Institute of Medical Genetics, Tomsk NRMC
Russian Federation
Russian Federation
I. A. Goncharova
Research Institute of Medical Genetics, Tomsk NRMC
Russian Federation
Russian Federation
M. V. Golubenko
Research Institute of Medical Genetics, Tomsk NRMC
Russian Federation
Russian Federation
References
1. Anderson JL, Horne BD, Stevens SM et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. Circulation. 2007. V. 116. P.2563-2570.
2. The International Warfarin Pharmacogenetics Consortium*Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. N Engl J Med 2009. V. 60. P.753-64.
3. Roth JA, Bradley K, Thummel KE et al. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiology and drug safety. 2015. V.24. P. 619-627. DOI: 10.1002/pds.3769
4. King CR, Deych E, Milligan P et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost. 2010. V.104(4). P. 750-754. doi:10.1160/TH09-11-0763.
5. Kamali X, Wulasihan M, Yang Y-C et al. Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. Lipids in Health and Disease. 2013. V. 12. P. 149-153. http://www.lipidworld.com/content/12/1/149
6. Kumar DK, Shewade DG, Loriot M-A et al. Effect of CYP2C9, VKORC1 , CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. Eur J Clin Pharmacol. 2014. V.70. P. 47-56. DOI 10.1007/s00228-013-1581-x
7. Li S, Zou Y, Wang X et al. Warfarin Dosage Response Related Pharmacogenetics in Chinese Population. PLoS ONE. 2015. V.10(1). e0116463. doi:10.1371/journal.
8. Rozen S., and Skaletsky H.J. Primer3 on the WWW for general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ, 2000. P. 365-386.
9. Lu G, Moriyama EN. Vector NTI, a balanced all-in-one sequence analysis suite. Brief Bioinform. 2004;5(4):378-388.
10. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose. PLoS Genet. 2009. V. 5(3): e1000433. doi:10.1371/journal.pgen.1000433
11. Cen H-J, Zeng W-T, Leng X-Y et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. V. 70 (2). P. 234-240. DOI:10.1111/j.1365-2125.2010.03698.x
12. Ferder NS, Eby CS, Deych E et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. J Thromb Haemost. 2010. V. 8. P. 95-100. DOI: 10.1111/j.1538-7836.2009.03677.x
13. Moreau C, Bajolle F, Siguret V et al. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012. V.119 (3). DOI 10.1182/blood-2011-07-365502.
14. Tian L, Zhang J, Xiao S et al. Impact of polymorphisms of the GGCX gene on maintenancewarfarin dose in Chinese populations: Systematic review and meta-analysis. Meta Gene. 2015. V. 5. P.43-5. http://dx.doi.org/10.1016/j.mgene.2015.05.003
15. Sun X 2, Yu W?Y, Ma W?L et al. Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. Biomedical Reports. 2016. V. 4. P.498-506. DOI: 10.3892/br.2016.599
Review
For citations:
Babushkina N.P., Goncharova I.A., Golubenko M.V. The developing of technology for diagnostics of genetic variants, that determine the sensitivity to warfarin, using the single nucleotide primer extension method. Medical Genetics. 2017;16(11):27-31. (In Russ.)
Views:
560
Email this article 